TArgeTed molecular Imaging and surgery for gastro intestinal Cancer
The treatment for cancer patients is shifting from population-based treatment to the more precise personalized medicine. Tumor-specific molecular diagnostics and treatment are an example of this phenomena to assist clinical decisi...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
FG_WIT
AUTOMATED PROTOTYPE OF CANCER DETECTION FROM CTDNA
75K€
Cerrado
CTQ2017-85658-R
TG-DIAG: NUEVAS ESTRATEGIAS DE DIAGNOSTICO BASADAS EN FLUORE...
116K€
Cerrado
CANCER-ID
Cancer treatment and monitoring through identification of ci...
21M€
Cerrado
MONOBREAST
Low-dose breast CT with monochromatic x-ray sources
150K€
Cerrado
GUIDE.MRD
GUIding multi-moDal thErapies against MRD by liquid biopsies...
34M€
Cerrado
PDC2021-121424-I00
BIOPSIA Y TEJIDO EN UN CHIP MAS BIOSENSORES MULTIPLEXADOS IN...
138K€
Cerrado
Información proyecto TAcTIC
Duración del proyecto: 18 meses
Fecha Inicio: 2019-07-11
Fecha Fin: 2021-01-31
Descripción del proyecto
The treatment for cancer patients is shifting from population-based treatment to the more precise personalized medicine. Tumor-specific molecular diagnostics and treatment are an example of this phenomena to assist clinical decision making and to improve treatment strategies for patients. This change in management will lead to societal benefits such as treatments that fits the patient’s needs and therefore, increased health benefits and increased quality-of-life. The targeted agent we have developed has both an imaging version to improve the detection and resection of cancer and an cytotoxic variant to eliminate potential remaining tumor cells. At this point, there is no agent available that can contribute to both the diagnostic phase and the subsequent treatment in a tumor-specific manner. Near infrared (NIR) fluorescence imaging is a technique that has gained a lot of attention over the last decade because of its role in intra-operative guidance to improve resection, and in, for example, endoscopy to improve detection. Combining a NIR-dye to a specific tumor-targeting ligand, like an antibody or a peptide, dramatically enhances the specificity, providing a solid real-time identification and demarcation technique. In TAcTIC, we propose the clinical introduction of a targeted fluorescent imaging agent against EpCAM, which can also be used for response monitoring during endoscopy, and the initiation of a New Company (in the Netherlands) via a joint venture between LUMC and ElevenBio (Boston, United States) for the future commercialization of this agent. The expected outcomes of this proof-of-concept project are the successful introduction of a novel targeted fluorescent agent for in multiple cancer types, a joint venture between LUMC and ElevenBio for the commercialization of this agent, and societal benefits for the patient in the form of increased health benefits and quality of life due to a treatment strategy that fits the individual patient’s needs.